シェーグレン症候群に伴う口腔乾燥症患者に対するピロカルピン塩酸塩の長期投与例の臨床的検討 第2報　─長期投与に伴う唾液分泌量，自覚症状スコアおよび副作用発現状況の推移─

DOI
  • 佐藤 真理子
    神奈川歯科大学総合歯科学講座 独立行政法人国立病院機構栃木医療センター臨床研究部
  • 石田 孝文
    独立行政法人国立病院機構栃木医療センター臨床研究部 神奈川歯科大学附属病院口腔外科
  • 岩渕 絵美
    独立行政法人国立病院機構栃木医療センター歯科口腔外科
  • 岩渕 博史
    独立行政法人国立病院機構栃木医療センター歯科口腔外科 神奈川歯科大学大学院歯学研究科顎顔面病態診断治療学講座顎顔面外科学分野

書誌事項

タイトル別名
  • A clinical study on the prolonged administration of pilocarpine hydrochloride for patients suffered from xerostomia due to Sjögren’s syndrome, second report：changes in the volume of salivary secretion, subjective symptom score, and incidence of adverse drug reactions in prolonged administration

この論文をさがす

抄録

<p>In patients receiving long-term administration of pilocarpine hydrochloride for the treatment of xerostomia associated with Sjögren’s syndrome, changes in the volume of salivary secretion, subjective symptom score, and incidence of adverse drug reactions were investigated. The subjects were 64 patients who received pilocarpine hydrochloride for 104 weeks or longer. We assessed changes in the volume of salivary secretion, subjective symptom score, incidence of adverse drug reactions, etc. during the treatment. The assessment revealed that the mean volume of salivary secretion significantly increased after 12 weeks of treatment, compared with that before the treatment. Then, the volume remained unchanged until week 104 of treatment. The mean subjective symptom score significantly decreased after 12 weeks of the treatment. Then, the mean score remained unchanged until week 104 of the treatment. In most patients, adverse drug reactions occurred soon after the treatment initiation, and there were a few patients who subsequently developed new adverse drug reactions. Moreover, hyperhidrosis and pollakisuria persisted for a long period in many patients. These findings suggested that pilocarpine hydrochloride remains effective for enhancing salivary secretion and relieving subjecting symptoms for at least 104 weeks after the treatment initiation. Additionally, long-term administration of the drug did not raise the incidence of adverse drug reactions.</p>

収録刊行物

  • 歯科薬物療法

    歯科薬物療法 37 (3), 117-124, 2018

    日本歯科薬物療法学会

キーワード

詳細情報 詳細情報について

問題の指摘

ページトップへ